Showing results (51-60 of 128) with videos related to
Sort By:
Pageof 13
CPT: Pharmacometrics & Systems Pharmacology|May 4, 2021
A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactionsSebastian Frechen, Juri Solodenko, Thomas Wendl, et al.Pharmaceutics|June 21, 2020
A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction StudiesNina Hanke, Denise Türk, Dominik Selzer, et al.Journal of Clinical Pharmacology|September 30, 2011
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationThorsten Lehr, Sebastian Haertter, Karl-Heinz Liesenfeld, et al.Clinical Pharmacokinetics|May 27, 2019
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and ItraconazoleDenise Türk, Nina Hanke, Sarah Wolf, et al.JAMA Internal Medicine|September 2, 2025
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical TrialThorsten Lehr, Peter Meiser, Dominik Selzer, et al.Cancer Chemotherapy and Pharmacology|October 9, 2017
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specificationDaniel Moj, Hannah Britz, Jürgen Burhenne, et al.Pharmaceutics|September 28, 2021
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel DiseaseChristina Schräpel, Lukas Kovar, Dominik Selzer, et al.Clinical Pharmacokinetics|March 14, 2020
Comprehensive Parent-Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy StrategiesLukas Kovar, Dominik Selzer, Hannah Britz, et al.The AAPS Journal|November 9, 2016
Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication RegimensDaniel Moj, Nina Hanke, Hannah Britz, et al.Cancer Chemotherapy and Pharmacology|May 11, 2016
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniquesMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.Pageof 13